These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36160880)

  • 1. Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma.
    Wang Z; He T; Yu D; Qin X; Geng A; Yang H
    Exp Ther Med; 2022 Oct; 24(4):625. PubMed ID: 36160880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib plus chemotherapy versus chemotherapy alone as neoadjuvant therapy in locally advanced gastric carcinoma patients: a prospective, cohort study.
    Sun Y; Fan Y; Ye Z; Dong J; Zhang L; Peng Y
    Ir J Med Sci; 2023 Jun; 192(3):1033-1040. PubMed ID: 35819743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study.
    Xu C; Xie X; Kang N; Jiang H
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4091-4099. PubMed ID: 36042044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
    Wan Y; Hui H; Wang X; Wu J; Sun S
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
    Chen H; Xue L; Liu L; Li P
    J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 7. Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma.
    Zheng Y; Wang Z; Yan C; Yan M; Hou Z; Zheng R; Zhu Z; Li C
    Ann Transl Med; 2020 Dec; 8(24):1684. PubMed ID: 33490196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study.
    Wang C; Wang Z; Zhao Y; Wang F
    J Gastric Cancer; 2023 Apr; 23(2):328-339. PubMed ID: 37129156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
    Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
    J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer.
    Xiong H; Li Y
    Am J Cancer Res; 2023; 13(8):3559-3570. PubMed ID: 37693166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.
    Lin JX; Xu YC; Lin W; Xue FQ; Ye JX; Zang WD; Cai LS; You J; Xu JH; Cai JC; Tang YH; Xie JW; Li P; Zheng CH; Huang CM
    JAMA Netw Open; 2021 Jul; 4(7):e2116240. PubMed ID: 34241629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.
    Zhang C; Wu B; Yang H; Yao Z; Zhang N; Tan F; Liu M; Xu K; Chen L; Xing J; Cui M; Su X
    BMC Cancer; 2022 Nov; 22(1):1223. PubMed ID: 36443694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 14. A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer.
    Lv X; Zhang L; Huang R; Song W
    Int J Clin Exp Med; 2015; 8(10):19030-6. PubMed ID: 26770529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
    Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
    Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
    Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
    Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.
    Jiang Q; Liu W; Zeng X; Zhang C; Du Y; Zeng L; Yin Y; Fan J; Yang M; Tao K; Zhang P
    Front Immunol; 2023; 14():1122121. PubMed ID: 37215127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects and safety of apatinib mesylate on patients with gastric carcinoma peritoneal metastasis in SOX scheme.
    Wang HF; Wang HH; Ye XJ; Wang WJ; Teng LS
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6627-6638. PubMed ID: 37522674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
    Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Safety and short-term efficacy of apatinib combined with oxaliplatin and S-1 in the conversion treatment for gastric cancer with peritoneal metastasis].
    Ye ZS; Zeng Y; Wei SH; Wang Y; Chen S; Lin ZT; Wang ZW; Chen XL; Chen LC
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):240-247. PubMed ID: 34645168
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.